Cargando…

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

OBJECTIVES: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor antibody) might interrupt the hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Conde, Matilde, Vizcarra, Pilar, Pérez-García, José Manuel, Gion, María, Martialay, María Pilar, Taboada, Javier, Alonso-Fernández, Alberto, Sampayo-Cordero, Miguel, Malfettone, Andrea, Tena, Isabel, Torre, Sergio De La, Llombart-Cussac, Antonio, Cortés, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384458/ https://www.ncbi.nlm.nih.gov/pubmed/35987472 http://dx.doi.org/10.1016/j.ijid.2022.08.007

Ejemplares similares

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021)

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2023)

Copérnico
por: Armitage, Angus
Publicado: (1952)

Copérnico
por: Banville, John
Publicado: (1990)

Copérnico
por: Coffa, José A.
Publicado: (1969)

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2021)

Nicolás Copérnico
por: Gortari, Elí de, 1918-1991
Publicado: (1975)

Nicolás Copérnico
Publicado: (1975)

Nobody dares stopping clinical research, not even COVID-19
por: Malfettone, Andrea, et al.
Publicado: (2021)

Nicolas Copérnico y su época
por: Adamczewski, Jan
Publicado: (1972)

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2019)

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
por: Pérez-García, José Manuel, et al.
Publicado: (2022)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
por: López-Miranda, Elena, et al.
Publicado: (2020)

La estatua de Nicolás Copérnico : homenaje en el V centenario de su natalicio.
Publicado: (1973)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?
por: Batista, Marta Vaz, et al.
Publicado: (2023)

Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity
por: Batista, Marta Vaz, et al.
Publicado: (2023)

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
por: Albanell, Joan, et al.
Publicado: (2023)

Application of Machine Learning in Hospitalized Patients with Severe COVID-19 Treated with Tocilizumab
por: Ramón, Antonio, et al.
Publicado: (2022)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Honrubia-Peris, Beatriz, et al.
Publicado: (2021)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
por: López González, Ana, et al.
Publicado: (2022)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”
por: Gion, Maria, et al.
Publicado: (2022)

Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
por: Chang, Anne Lynn S., et al.
Publicado: (2018)

Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers
por: Martínez-Sanz, Javier, et al.
Publicado: (2021)

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2021)

Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
por: Oommen, Tiffany T., et al.
Publicado: (2023)

Low risk of bacterial co-infection, opportunistic diseases, and persistent immunosuppression in people living with HIV and COVID-19
por: Casado, José L., et al.
Publicado: (2022)

Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility
por: Albóniga, Oihane E., et al.
Publicado: (2023)

Tocilizumab in patients infected by SARS-CoV2()
por: Sancho, Milagros, et al.
Publicado: (2021)

Tocilizumab en el paciente con COVID-19
por: Sancho, Milagros, et al.
Publicado: (2021)

Isolation of exosomes from whole blood by a new microfluidic device: proof of concept application in the diagnosis and monitoring of pancreatic cancer
por: Sancho-Albero, María, et al.
Publicado: (2020)

The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
por: Rubio-Rivas, Manuel, et al.
Publicado: (2021)

Implementation of a lung cancer screening initiative in HIV-infected subjects
por: Díaz-Álvarez, Jorge, et al.
Publicado: (2021)

A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic Target
por: Fernández-Murga, M. Leonor, et al.
Publicado: (2023)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: de la Cruz-Merino, Luis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vd2sl9dut6r98mmh5hkb1685jf